Boston Scientific’s fourth-quarter profit and sales climbed but the medical-device maker issued a soft forecast for the year, sending shares down in premarket trading.
The company logged earnings of $672 million, or 45 cents a share, up from $562 million, or 38 cents a share, a year earlier.
Adjusted earnings rose to 80 cents a share compared with mean analyst estimates of 78 cents a share as per FactSet.
Sales rose 16% to $5.29 billion, edging the average Wall Street forecast of $5.28 billion, according to FactSet. Sales at its cardiovascular unit rose 18% to $3.48 billion, while MedSurg sales increased 12% to $1.81 billion.
Shares recently slipped 10.3% to $82.22 premarket.
For the first quarter, Boston Scientific is targeting adjusted earnings in a range between 78 cents and 80 cents a share, with sales growth of about 10.5% to 12%, or 8.5% to 10% on an organic basis, excluding the impact of skew factors such as acquisitions and foreign exchange. Analysts currently expect first-quarter adjusted earnings at 80 cents a share.
For 2026, the company forecast adjusted earnings in a range between $3.43 and $3.49 a share, up from $3.06 a share in 2025, compared with analysts’ estimates of $3.47 a share. Boston Scientific anticipates sales growth of 10.5% to 11.5% for the year, or 10% to 11% on an organic basis.
Last month, Boston Scientific agreed to a $15 billion deal to acquire thrombectomy company Penumbra in a bid to enter new, fast-growing segments within the vascular space.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.